FilingSEC EDGAR8-K
Moleculin Biotech Announces Preclinical Data for Pancreatic Cancer Candidate
· SEC accepted
Stagepreclinical
Filing content
The company presented preclinical data at the AACR conference indicating that its drug candidate Annamycin exhibits antitumor activity in pancreatic cancer models mediated by CD8+ T cells.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…